Livraison suivie dans le monde entier | Env. 9–14 jours ouvrés

Votre panier

Votre panier est vide

Commencer à parcourir

Livraison gratuite pour les commandes de plus de €500.

Sous-total€0
Passer à la caisse
HormonesMédicament approuvé

HMG

Recherche publiée et base de preuves

Human menopausal gonadotropin (menotropins) is a urinary-derived gonadotropin preparation containing both follicle-stimulating hormone and luteinizing hormone activity, the latter contributed substantially by chorionic gonadotropin retained during purification. Highly purified formulations (hp-hMG) have been evaluated against recombinant FSH and against rFSH plus recombinant LH in a large randomised-controlled-trial literature covering ovarian stimulation for IVF/ICSI, ovulation induction, and combined gonadotropin therapy for spermatogenesis induction in male hypogonadotropic hypogonadism. A 2026 Cochrane update reported probable advantages for hMG/hp-hMG over rFSH in live birth and ovarian hyperstimulation syndrome, while other recent systematic reviews found comparable live birth with differing oocyte yields, and the field remains characterised by heterogeneity in dosing, protocol and endpoint definition.

En bref
  • L'HMG est une préparation hormonale urinaire contenant FSH et activité LH.
  • Des essais humains ont rapporté des avantages probables sur rFSH pour naissances vivantes et SHSO.
  • Les données varient selon protocole et type de répondeuse ; dosage optimal flou.

37 études · 16 depuis 2023 · plus récente 2026

Études citées
37
Publiées 2023+
16
Article le plus récent
2026
Dernière révision
oct. 2026

Thèmes récurrents dans la littérature

  • ovarian stimulation for IVF/ICSI
  • combined FSH and LH activity
  • highly purified hMG versus recombinant FSH
  • live birth and cumulative live birth rate
  • ovarian hyperstimulation syndrome risk
  • GnRH antagonist protocols and predicted high responders
  • poor ovarian response and LH supplementation
  • follicular steroidogenesis and premature progesterone elevation
  • ovulation induction in polycystic ovary syndrome
  • spermatogenesis induction in male hypogonadotropic hypogonadism

Identifiants du composé

Les preuves

37 études publiées.

Classées par rigueur du protocole d'étude, puis par date. Chaque entrée renvoie à sa source pour que les résultats puissent être vérifiés dans l'article plutôt que pris sur parole.

  1. 01Directive clinique2023

    Use of gonadotropins in ovarian stimulation in Spain: Delphi consensus

    Barrenetxea G, et al. · Journal of Obstetrics and Gynaecology · modified Delphi consensus among Spanish reproductive medicine specialists

    Consensus statements supported FSH monotherapy for younger normal and hyper-responder patients, with LH-containing preparations such as hMG considered in defined subgroups including advanced age and hypo-response.

  2. 02Revue systématique2026

    Recombinant follicle-stimulating hormone (rFSH) versus other recombinant or urinary gonadotropins for ovarian stimulation in assisted reproductive technology cycles

    Berkhout RP, et al. · Cochrane Database of Systematic Reviews · Cochrane systematic review and meta-analysis of randomised trials comparing rFSH with urinary and other recombinant gonadotropins

    Live birth and clinical pregnancy were probably lower with rFSH than with hMG/hp-hMG, and ovarian hyperstimulation syndrome was probably higher with rFSH; certainty of evidence was rated moderate for the principal comparisons.

  3. 03Revue systématique2026

    Luteinizing hormone activity in ovarian stimulation: comparative efficacy and safety of gonadotropins versus recombinant follicle-stimulating hormone-a systematic review and meta-analysis

    Espinós JJ, et al. · Frontiers in Endocrinology · systematic review and meta-analysis of randomised trials of LH-activity-containing gonadotropins versus rFSH alone

    Gonadotropins carrying LH activity probably produced little to no difference in live birth or ongoing pregnancy compared with rFSH alone, but were associated with a more favourable ovarian hyperstimulation syndrome profile.

  4. 04Revue systématique2026

    Comparative Effectiveness of Recombinant Human Follicle-Stimulating Hormone:Recombinant Human Luteinizing Hormone in a 2:1 Ratio versus Highly Purified Human Menopausal Gonadotropin Alone in Ovarian Stimulation for Medically Assisted Reproduction Treatment Using in vitro Fertilization/Intracytoplasmic Sperm Injection: A Systematic Review and Meta-Analysis

    Dahan MH, et al. · Gynecologic and Obstetric Investigation · systematic review and meta-analysis of six studies, 5,287 stimulation cycles

    Oocyte yield was significantly higher with r-hFSH:r-hLH in a 2:1 ratio than with hp-hMG alone and clinical pregnancy rate favoured the recombinant combination, but data were insufficient to draw firm conclusions on live birth.

  5. 05Revue systématique2025

    Controlled ovarian stimulation protocols for assisted reproduction: a network meta-analysis

    Melo P, et al. · Cochrane Database of Systematic Reviews · Cochrane network meta-analysis of randomised trials of controlled ovarian stimulation protocols

    Short GnRH antagonist protocols may have reduced ovarian hyperstimulation syndrome in women with predicted normal response without an evident reduction in live birth or ongoing pregnancy; comparisons between individual gonadotropin preparations were limited by network sparsity.

  6. 06Revue systématique2025

    Evaluating Sperm Recovery Time and Efficacy of Monotherapy vs. Combination Therapies in Men with Congenital Hypogonadotropic Hypogonadism: A Systematic Review and Meta-Analysis

    Pozzi E, et al. · The World Journal of Men's Health · systematic review and meta-analysis of studies in men with congenital hypogonadotropic hypogonadism treated with hCG alone or hCG combined with FSH/hMG

    Combination gonadotropin therapy was associated with shorter time to sperm appearance and higher sperm recovery rates than hCG monotherapy.

  7. 07Revue systématique2025

    Gonadotropins for ovulation induction in women with polycystic ovary syndrome.

    Weiss NS, et al. · Cochrane Database Syst Rev · Cochrane systematic review, 15 RCTs, n=2,348 women with PCOS

    For HMG versus urinary FSH (3 RCTs) the evidence was very low certainty and did not establish differences in live birth, multiple pregnancy, miscarriage or OHSS; rFSH versus urinary-derived gonadotropins showed little or no difference in live birth.

  8. 08Revue systématique2025

    An umbrella review of meta-analyses regarding the incidence of female-specific malignancies after fertility treatment.

    Saso S, et al. · Fertil Steril · umbrella review of 11 meta-analyses (188 studies)

    Fertility treatment was associated with higher incidence of ovarian cancer (OR 1.21) and borderline ovarian tumours (OR 1.87); for borderline tumours, hMG-only (OR 3.46) and hMG plus clomiphene (OR 3.79) regimens were associated with higher incidence, but no association reached strong or highly suggestive evidence.

    Résultat de sécurité signalé. hMG-only regimens were associated with more borderline ovarian tumours in pooled observational data, with weak evidence grading.

  9. 09Revue systématique2024

    Gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism: systematic review and meta-analysis

    Alexander EC, et al. · European Journal of Endocrinology · systematic review and meta-analysis of gonadotropin regimens, including hCG plus hMG or FSH, for pubertal induction in male hypogonadotropic hypogonadism

    Gonadotropin regimens increased testicular volume and induced pubertal development, but protocols were highly heterogeneous and randomised comparisons were largely absent.

  10. 10Revue systématique2019

    Required amount of rFSH, HP-hMG and HP-FSH to reach a live birth: a systematic review and meta-analysis

    Bordewijk EM, et al. · Human Reproduction Open · systematic review and meta-analysis of 28 studies including 7,553 women

    Differences between rFSH, hp-hMG and hp-FSH in total gonadotropin required per live birth were small, leading the authors to conclude that selection could reasonably rest on availability, cost and patient preference.

  11. 11Revue systématique2008

    Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis

    Coomarasamy A, et al. · Human Reproduction · meta-analysis of seven randomised trials, 2,159 women, GnRH agonist long protocol

    hMG was associated with a pooled increase of approximately 4 percentage points in live birth rate relative to rFSH in agonist long-protocol IVF/ICSI cycles.

  12. 12Clinique humaine2026

    Human menopausal gonadotrophin in a pre-filled injection pen is non-inferior to the US-approved powder formulation

    Witz C, et al. (CLARA trial group) · Reproductive BioMedicine Online · randomised non-inferiority trial of hp-hMG solution in a pre-filled pen versus the approved lyophilised powder formulation

    The pre-filled pen solution met non-inferiority criteria against the powder formulation on the primary stimulation endpoint, with comparable safety observations reported between arms.

  13. 13Clinique humaine2026

    Blastocyst Morphology in Oocyte Donors stimulated During the Late Follicular Phase with either rFSH:rLH or HP-hMG in a PPOS protocol: a Pilot Randomized Controlled Trial.

    Castillo-Velásquez F, et al. · JBRA Assist Reprod · pilot randomised controlled trial, healthy oocyte donors (40 per group) in a progestin-primed protocol, late-follicular recombinant FSH plus LH versus HP-hMG after initial recombinant FSH

    Good-quality blastocysts were more numerous with recombinant FSH plus LH than with HP-hMG (3.4 vs 2.3), with no difference in total gonadotropin use, stimulation length or oocytes retrieved.

  14. 14Clinique humaine2025

    Impact of gonadotropin selection on risk of ovarian hyperstimulation syndrome in predicted high responders: a Menopur in Gonadotropin-releasing hormone Antagonist Single Embryo Transfer-High Responder trial analysis

    Foulk R, et al. · F&S Reports · secondary analysis of the MEGASET-HR randomised trial, 620 women with AMH >=5 ng/mL

    After adjustment for oocyte yield, hp-hMG was associated with significantly lower rates of ovarian hyperstimulation syndrome than rFSH in predicted high responders under a GnRH antagonist protocol.

  15. 15Clinique humaine2025

    Comparison of outcomes between pulsatile gonadotropin releasing hormone and combined gonadotropin therapy of spermatogenesis in patients with congenital hypogonadotropic hypogonadism.

    Zheng Y, et al. · Reprod Biol Endocrinol · single-centre retrospective cohort, n=155 post-pubertal men with congenital hypogonadotropic hypogonadism, pulsatile GnRH versus hCG/hMG for at least 6 months

    Spermatogenesis was induced in similar proportions (82.1% with pulsatile GnRH vs 75.8% with hCG/hMG), but pulsatile GnRH took less time (12.34 vs 14.74 months) and gave a larger final testicular volume (15 vs 12 ml). Larger baseline testicular volume predicted success.

  16. 16Clinique humaine2025

    Clinical efficacy and safety of two highly purified human menopausal gonadotropins in women undergoing in vitro fertilization.

    Rao KA, et al. · Reprod Fertil · multicentre randomised active-controlled noninferiority trial, n=150 women aged 21-40 in their first or second IVF cycle, Gynogen HP versus Menopur (both highly purified hMG)

    Oocytes retrieved were similar (6.3 vs 6.7), meeting noninferiority, and secondary efficacy endpoints and safety did not differ significantly between the two preparations.

  17. 17Clinique humaine2024

    Serum progesterone is lower in ovarian stimulation with highly purified HMG compared to recombinant FSH owing to a different regulation of follicular steroidogenesis: a randomized controlled trial

    Bosch E, et al. · Human Reproduction · randomised controlled trial in 112 oocyte donors (56 per arm), hp-hMG versus rFSH

    Late-follicular serum progesterone was lower with hp-hMG than rFSH, attributed to a shift toward the delta-4 steroidogenic pathway rather than to differences in follicular recruitment.

  18. 18Clinique humaine2020

    Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection

    Witz CA, et al. · Fertility and Sterility · MEGASET-HR randomised assessor-blinded equivalence trial, 620 predicted high responders (AMH >=5 ng/mL), GnRH antagonist protocol with single blastocyst transfer

    hp-hMG achieved ongoing pregnancy rates equivalent to rFSH despite lower oocyte yield, with fewer adverse events including ovarian hyperstimulation syndrome and early pregnancy loss.

  19. 19Clinique humaine2019

    Treatment of idiopathic oligozoospermia with combined human chorionic gonadotropin/human menopausal gonadotrophin: A randomised, double-blinded, placebo-controlled clinical study.

    Zhao N, et al. · Andrologia · randomised double-blind placebo-controlled trial, Chinese men with idiopathic oligozoospermia, hCG/hMG versus placebo, 3 months

    In men with medium or higher inhibin B, hCG/hMG improved sperm concentration, forward motility, total motile count, normal morphology and spontaneous pregnancy rate and lowered the DNA fragmentation index, while men with low inhibin B showed no significant change.

  20. 20Clinique humaine2017

    Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.

    Drakopoulos P, et al. · Hum Reprod · multicentre phase III randomised superiority trial, n=152 poor ovarian responders under 40 meeting the Bologna criteria, corifollitropin alfa followed by highly purified hMG versus recombinant FSH in a GnRH antagonist protocol

    Ongoing pregnancy did not differ (14.3%, 11/77, vs 15.7%, 11/70), nor did live birth or oocyte numbers, but more women in the corifollitropin plus hp-HMG group had embryos cryopreserved (28.6% vs 14.3%). The authors noted the trial may have been underpowered.

  21. 21Clinique humaine2017

    A randomized controlled trial comparing the efficacy and safety of two HMG preparations gaining their LH bioactivity from different HCG sources.

    Lockwood G, et al. · Reprod Biomed Online · multicentre randomised non-inferiority trial, n=270 women aged 18 to 39 having IVF with a long GnRH agonist protocol, two hMG preparations whose LH activity comes from different hCG sources (Menopur versus Meriofert)

    Embryo quality, fertilisation, implantation, ongoing pregnancy and live birth did not differ significantly. More oocytes were retrieved with the new preparation (11.6 vs 9.7) after a shorter stimulation, and OHSS frequency was the same.

  22. 22Clinique humaine2015

    Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT.

    Moro F, et al. · Hum Reprod · single-centre randomised controlled trial, 579 women aged 35 or older with unexplained infertility or mild male factor having intrauterine insemination, highly purified hMG (Meropur) versus recombinant FSH plus recombinant LH

    Ongoing pregnancy was 12.2% (35/289) with HP-hMG and 17.3% (48/290) with rFSH plus rLH (odds ratio 1.50, P = 0.09), not a significant difference. Cycles interrupted for high OHSS risk were fewer with HP-hMG (0.7% vs 4.5%), and the trial closed early.

  23. 23Clinique humaine2015

    Low-dose human menopausal gonadotrophin versus clomiphene citrate in subfertile couples treated with intrauterine insemination: a randomized controlled trial.

    Peeraer K, et al. · Hum Reprod · open-label randomised clinical trial, n=330 women (657 cycles) with mild male subfertility, unexplained subfertility or minimal-mild endometriosis having intrauterine insemination, low-dose subcutaneous hMG versus oral clomiphene citrate

    Per cycle, hMG gave higher clinical pregnancy (14.4% vs 9.0%; RR 1.6) and live birth (13.8% vs 8.7%) than clomiphene, with low and comparable multiple live birth (6.5% vs 3.6%) and fewer cancelled cycles (4.7% vs 15.4%).

  24. 24Clinique humaine2013

    Advantages of recombinant follicle-stimulating hormone over human menopausal gonadotropin for ovarian stimulation in intrauterine insemination: a randomized clinical trial in unexplained infertility.

    Rashidi M, et al. · Eur J Obstet Gynecol Reprod Biol · prospective randomised clinical trial, couples with unexplained infertility having intrauterine insemination, clomiphene plus hMG (n=127) versus clomiphene plus recombinant FSH (n=132)

    Stimulation was shorter and total gonadotropin use lower with rFSH. Clinical pregnancy, multiple pregnancy, miscarriage, live birth, OHSS and cancellation rates did not differ significantly.

  25. 25Clinique humaine2012

    A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer.

    Devroey P, et al. · Fertil Steril · multicentre assessor-blind noninferiority RCT, n=749 women, 25 centres in 7 countries

    Highly purified hMG was noninferior to rFSH for ongoing pregnancy after a fresh cycle (29% vs 27%, intention-to-treat), and cumulative live birth rates including frozen transfers within one year were 40% and 38%.

  26. 26Clinique humaine2012

    Outcome of in vitro fertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: a prospective, randomized and controlled trial.

    Ye H, et al. · Gynecol Endocrinol · prospective randomised controlled trial, n=127 normogonadotropic infertile women aged 35 or older in their first IVF/ICSI cycle with a long GnRH agonist protocol, highly purified hMG (n=63) versus recombinant FSH (n=64)

    rFSH produced more leading follicles and oocytes and higher end-of-stimulation progesterone. Top-quality embryos and live birth per started cycle trended higher with HP-hMG (live birth OR 1.9, 95% CI 0.9-3.9) without a significant difference, and non-inferiority was established.

  27. 27Clinique humaine2011

    A prospective randomized noninferiority study comparing recombinant FSH and highly purified menotropin in intrauterine insemination cycles in couples with unexplained infertility and/or mild-moderate male factor.

    Sagnella F, et al. · Fertil Steril · prospective randomised noninferiority trial, five hundred twenty-three patients with unexplained or mild male-factor infertility having intrauterine insemination, highly purified hMG (261) versus recombinant FSH (262)

    Clinical pregnancy was 19.7% with HP-hMG and 21.4% with rFSH, meeting noninferiority. Cycles interrupted for OHSS risk and multiple pregnancy were more frequent with rFSH (8.4% vs 1.2%).

  28. 28Clinique humaine2010

    Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial.

    Pacchiarotti A, et al. · Fertil Steril · multicentre prospective randomised controlled trial, n=122 IVF patients, urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris)

    Pregnancy and implantation rates and oocyte and embryo quality were comparable, with an increased risk of ovarian hyperstimulation in the recombinant FSH plus LH group.

  29. 29Clinique humaine2008

    Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients.

    Hompes PG, et al. · Fertil Steril · open-label randomised comparison in eighteen Dutch IVF centres, six hundred twenty-nine first-cycle IVF/ICSI patients after GnRH agonist suppression, highly purified hMG versus recombinant FSH

    Ongoing pregnancy per started cycle was 26.3% with HP-hMG and 25.2% with rFSH. HP-hMG gave fewer oocytes (7.8 vs 10.6) and fewer cycles cancelled for ovarian hyperresponse (2.0% vs 6.0%), with similar fertilisation and implantation rates.

  30. 30Clinique humaine2008

    Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists--a randomized study.

    Bosch E, et al. · Hum Reprod · randomised controlled trial, n=280 women having IVF/ICSI with a GnRH antagonist protocol, highly purified hMG versus recombinant FSH

    Ongoing pregnancy per started cycle did not differ (35.0% vs 32.1%; relative risk 1.09), nor did implantation, clinical pregnancy or pregnancy loss. rFSH yielded more oocytes (14.4 vs 11.3); estradiol at the end of stimulation was higher with hp-hMG and progesterone higher with rFSH.

  31. 31Clinique humaine2006

    Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial.

    Andersen AN, et al. · Hum Reprod · randomised assessor-blind multinational trial, n=731 women having IVF after a long GnRH agonist protocol, highly purified hMG (n=363) versus recombinant FSH (n=368)

    Ongoing pregnancy was 27% with HP-hMG and 22% with rFSH (odds ratio 1.25, 95% CI 0.89-1.75), establishing non-inferiority but not superiority. rFSH yielded more oocytes (11.8 vs 10.0), a higher proportion of HP-hMG oocytes became top-quality embryos (11.3% vs 9.0%), and progesterone at the end of stimulation was higher with rFSH.

  32. 32Clinique humaine2006

    Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study.

    Platteau P, et al. · Hum Reprod · randomised open-label assessor-blind multinational non-inferiority trial, clomiphene-resistant women with WHO Group II anovulatory infertility, highly purified hMG (n=91) versus recombinant FSH (n=93) for ovulation induction

    Ovulation rates were 85.7% with HP-hMG and 85.5% with rFSH, meeting non-inferiority, and singleton live birth rates were comparable. Fewer intermediate-sized follicles developed with HP-hMG, and OHSS and/or cancellation for excessive response occurred in 2.2% versus 9.8% (P=0.058).

  33. 33Clinique humaine2005

    Subcutaneously administered Menopur, a new highly purified human menopausal gonadotropin, causes significantly fewer injection site reactions than Repronex in subjects undergoing in vitro fertilization.

    Keye WR, et al. · Reprod Biol Endocrinol · randomised open-label parallel-group multicentre study, n=125 women aged 18-39 having IVF, subcutaneous Menopur (highly purified hMG, n=61) versus subcutaneous Repronex (hMG, n=64)

    Significantly fewer women reported injection-site reactions with Menopur than with Repronex, and the overall incidence of adverse events did not differ significantly.

  34. 34Clinique humaine2003

    A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes.

    Kilani Z, et al. · Hum Reprod · prospective randomised controlled trial, n=100 infertile women having ICSI after GnRH agonist suppression, highly purified hMG (50) versus recombinant FSH-alpha (50)

    HP-hMG needed a shorter stimulation (11.1 vs 12.9 days) and less gonadotrophin, and gave higher peak estradiol and measurable serum hCG during treatment. Pregnancy per started cycle (30% vs 28%) and miscarriage (6% vs 6%) did not differ.

  35. 35Clinique humaine2002

    Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial

    European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone · Fertility and Sterility · multicentre randomised comparative phase III trial, 781 women enrolled (373 hp-hMG, 354 rFSH)

    Ongoing pregnancy rates were equivalent between hp-hMG and rFSH, with similar safety and tolerability profiles, establishing the reference comparison for later trials.

  36. 36Clinique humaine1987

    Treatment of severe oligospermia with human chorionic gonadotropin/human menopausal gonadotropin: a placebo-controlled, double blind trial.

    Knuth UA, et al. · J Clin Endocrinol Metab · double-blind placebo-controlled randomised trial, 39 normogonadotropic men with oligospermia, intramuscular hCG plus hMG (nineteen men) versus saline (20 men), 13 weeks

    Sperm concentration, motility and morphology were similar in the two groups at all time points. Two pregnancies occurred in partners of men given hCG-hMG and none in the placebo group.

  37. 37Revue2025

    Does HCG and LH supplementation during ovarian stimulation improve clinical outcome? An evaluation of 30 years of clinical research

    Mannaerts B, Yding Andersen C, Howles CM · Reproductive BioMedicine Online · narrative review of three decades of clinical research on hCG and LH supplementation, including hMG preparations

    The authors concluded that a beneficial effect of hCG or LH supplementation on clinical outcome had never been definitively demonstrated for any combined gonadotropin product.

Limites

Ce que ces preuves n'établissent pas.

Head-to-head randomised data remain insufficient to establish whether hMG or hp-hMG changes cumulative live birth rate across fresh and subsequent frozen transfers, and the magnitude of any live birth advantage over recombinant FSH varies by protocol, responder phenotype and trial era. Evidence in poor responders under POSEIDON criteria, in freeze-all strategies, and in male hypogonadotropic hypogonadism is dominated by small, heterogeneous and largely non-randomised studies, and no consensus exists on optimal LH-activity dosing.

Questions courantes sur la recherche.

What is HMG?

HMG (human menopausal gonadotropin, also called menotropin) is a urine-derived biologic preparation containing both follicle-stimulating hormone and luteinising hormone activity, conventionally in an approximately 1:1 ratio by international unit.

How does it differ from recombinant FSH?

Recombinant FSH supplies FSH activity only, produced in cell culture. HMG is extracted from urine and supplies both FSH and LH activity, with part of the LH activity contributed by chorionic gonadotropin present in the preparation. The Cochrane comparison of the two classes across 42 trials found no statistically significant difference in live birth rate.

What does the research report about ovarian hyperstimulation syndrome risk?

A 2026 Cochrane systematic review reported that ovarian hyperstimulation syndrome was probably higher with recombinant FSH than with hMG or highly purified hMG, at moderate certainty of evidence. A secondary analysis of the MEGASET-HR randomised trial in 620 women with AMH of 5 ng/mL or above found significantly lower rates of the syndrome with highly purified hMG than with recombinant FSH under a GnRH antagonist protocol, after adjustment for oocyte yield. No consensus exists in this literature on optimal LH-activity dosing.

Disponible dans notre catalogue

À des fins de recherche uniquement. Non destiné à la consommation humaine, au diagnostic, au traitement ou à la prévention de toute condition. Rien sur cette page ne constitue un avis médical, et aucune étude résumée ici ne doit être considérée comme une recommandation.